Entrada Therapeutics, Inc. (NASDAQ:TRDA) Insider Natarajan Sethuraman Sells 600 Shares

Entrada Therapeutics, Inc. (NASDAQ:TRDA) insider Natarajan Sethuraman sold 600 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $18.00, for a total value of $10,800.00. Following the completion of the transaction, the insider now directly owns 183,216 shares in the company, valued at approximately $3,297,888. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Natarajan Sethuraman also recently made the following trade(s):

• On Monday, September 9th, Natarajan Sethuraman sold 2,642 shares of Entrada Therapeutics stock. The stock was sold at an average price of $15.09, for a total value of $39,867.78.
• On Friday, September 6th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The shares were sold at an average price of $15.24, for a total transaction of $9,144.00.

Entrada Therapeutics Trading Down 1.1 %

Shares of Entrada Therapeutics stock opened at $17.44 on Friday. The stock has a market cap of $648.77 million, a PE ratio of 5.89 and a beta of -0.25. The company has a 50-day moving average of $16.01 and a two-hundred day moving average of $15.19. Entrada Therapeutics, Inc. has a 12-month low of $10.75 and a 12-month high of $18.17.

Entrada Therapeutics (NASDAQ:TRDA) last posted its earnings results on Tuesday, August 13th. The company reported $1.55 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.90. Entrada Therapeutics had a return on equity of 35.16% and a net margin of 43.63%. The company had revenue of $94.69 million for the quarter, compared to the consensus estimate of $55.00 million. On average, sell-side analysts forecast that Entrada Therapeutics, Inc. will post 0.68 EPS for the current fiscal year.

Analysts Set New Price Targets

TRDA has been the subject of several recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Entrada Therapeutics in a report on Wednesday, August 14th. Oppenheimer restated an “outperform” rating and set a $25.00 target price on shares of Entrada Therapeutics in a research report on Monday, August 26th.

Institutional Investors Weigh In On Entrada Therapeutics

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in Entrada Therapeutics by 1.3% during the first quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company’s stock worth $15,288,000 after acquiring an additional 13,742 shares during the last quarter. American Century Companies Inc. increased its stake in shares of Entrada Therapeutics by 5.1% during the 2nd quarter. American Century Companies Inc. now owns 384,973 shares of the company’s stock worth $5,486,000 after purchasing an additional 18,625 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Entrada Therapeutics by 13.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 125,436 shares of the company’s stock worth $1,787,000 after purchasing an additional 14,838 shares during the last quarter. Marshall Wace LLP lifted its stake in Entrada Therapeutics by 27.5% in the 2nd quarter. Marshall Wace LLP now owns 65,943 shares of the company’s stock valued at $940,000 after buying an additional 14,220 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in Entrada Therapeutics by 3.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 57,098 shares of the company’s stock valued at $814,000 after buying an additional 2,146 shares during the last quarter. 86.39% of the stock is owned by institutional investors and hedge funds.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.